Key Takeaway
Optimi Health Corp. (NASDAQ: OPTH) is expected to list on 2026-05-20, with a price range not disclosed and 2,500,000 shares offered. The setup is a small, early commercial psychedelic manufacturer with real revenue, but it is still carrying losses, a working capital deficit, and heavy regulatory dependence.
Quick Facts
Expected listing date: May 20, 2026
Exchange: NASDAQ
Proposed symbol: OPTH
Shares offered: 2.50M shares
Implied market cap: $23M
Status: Expected
Company Overview
Optimi Health Corp. is a commercial-stage psychedelic drug manufacturer focused on finished-dose psilocybin and MDMA capsules. The company says it operates a Health Canada Drug Establishment-licensed, GMP-compliant facility in Princeton, British Columbia, and supplies products to authorized prescribers in Australia under the TGA Authorized Prescriber Scheme. It also says it is built to scale into additional jurisdictions as regulation develops, including the U.S. if federal rescheduling occurs.
The business is still narrow in scope and geography. In the filing, Optimi disclosed only a single customer-related deferred revenue balance of C$207,759 as of December 31, 2025, tied to deposits for drug product purchase orders, and it expected commercial shipments valued at C$93,000 to that customer in January 2026. The company was incorporated on May 27, 2020, changed its name to Optimi Health Corp. on August 17, 2020, and is headquartered at 269 David Brown Way, Princeton, British Columbia.
Why They're Going Public
Optimi says it expects to use net proceeds to scale production and distribution of its products, expand into new markets, support sales growth, fund general working capital, and cover other operating expenses. Management will have broad discretion over how the proceeds are deployed.
